Browse Studies — Arctuva

Phase 2

A Phase 2 Open-label Study to Evaluate Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Primary or Secondary Myelofibrosis

The purpose of this Phase 2 study is to evaluate the efficacy and safety of momelotinib (MMB) in combination with luspatercept (LUSPA) in participants with tra…

Primary MyelofibrosisMyelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT06517875

Phase 1

Feasibility Study of CD34 Selection for GVHD Prophylaxis Using the Automated CliniMACS

Patients with graft failure or delayed engraftment may benefit from a hematopoietic stem cell boost or an additional hematopoietic stem cell transplantation pr…

AMLALLLymphoid Malignancies+3 more

Estimated

~$10 – $6,250

University of Alabama at BirminghamNCT06047886

Phase 1

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With Ruxolitinib in Janus-associated Kinase Inhibitor (JAKi) Treatment-Naïve Myelofibrosis (MF) Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Partici…

MyelofibrosisPrimary MyelofibrosisPost-PV MF+1 more

Estimated

~$10 – $8,750

Telios Pharma, Inc.NCT05280509

Phase 3

A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study

The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include pa…

Thrombocythemia, EssentialPrimary MyelofibrosisMyelofibrosis+3 more

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT06351631